一种评估新型类风湿性关节炎药物——吡洛芬疗效的双重方法。
A dual approach to the evaluation of the efficacy of a new rheumatoid arthritic agent--pirprofen.
作者信息
Maggio-Cavaliere M B, Bonus L, Gum O B
出版信息
J Clin Pharmacol. 1976 Jan;16(1):8-18. doi: 10.1002/j.1552-4604.1976.tb01486.x.
Pirprofen was compared to placebo in a double-blind crossover study in 12 rheumatoid arthritis patients. Two approaches--univariate and multivariate--were used to analyze the study results which were in the form of arithmetic changes from pretreatment levels of six efficacy measurements. The univariate analysis failed to permit a single decision to be made regarding the further investigation and use of pirprofen in rheumatoid arthritis. However, the multivariate analysis which treats the efficacy variables simultaneously showed a clear differentation from placebo. Thus, multivariate analysis enabled the clinical pharmacologist to evaluate the new therapeutic agent in a complete and comprehensive manner. It allowed for a single decision to be made regarding the merits of pirprofen compared to placebo.
在一项针对12名类风湿性关节炎患者的双盲交叉研究中，将吡洛芬与安慰剂进行了比较。采用单变量和多变量两种方法分析研究结果，这些结果以六项疗效测量指标相对于治疗前水平的算术变化形式呈现。单变量分析未能就吡洛芬在类风湿性关节炎中的进一步研究和使用做出单一决策。然而，同时处理疗效变量的多变量分析显示出与安慰剂有明显差异。因此，多变量分析使临床药理学家能够以完整和全面的方式评估这种新治疗药物。它使得能够就吡洛芬相对于安慰剂的优点做出单一决策。
Zotero 插件